NCT05070156View on ClinicalTrials.gov

B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

September 30, 2024

Conditions
Advanced Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Biological/Vaccine: Low-dose group

1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.

BIOLOGICAL

Biological/Vaccine: Mid-dose group

2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.

BIOLOGICAL

Biological/Vaccine: High-dose group

3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.

Trial Locations (1)

200072

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

lead

Tongji University

OTHER